P-selectin and sickle cell disease: a balancing act.
作者信息
Manwani Deepa
机构信息
Albert Einstein College of Medicine.
出版信息
Blood. 2021 May 13;137(19):2573-2574. doi: 10.1182/blood.2021011151.
Abstract
摘要
相似文献
1
P-selectin and sickle cell disease: a balancing act.
Blood. 2021 May 13;137(19):2573-2574. doi: 10.1182/blood.2021011151.
2
Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
Blood Cells Mol Dis. 2020 Jul;83:102424. doi: 10.1016/j.bcmd.2020.102424. Epub 2020 Mar 10.
3
The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.
Blood. 2004 Nov 15;104(10):3378-85. doi: 10.1182/blood-2004-02-0713. Epub 2004 Jul 22.
4
Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.
Blood. 2011 Jan 13;117(2):727-35. doi: 10.1182/blood-2010-05-285718. Epub 2010 Oct 6.
5
P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.
Blood. 2001 Sep 15;98(6):1955-62. doi: 10.1182/blood.v98.6.1955.
6
Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.
Clin Appl Thromb Hemost. 2016 Apr;22(3):230-8. doi: 10.1177/1076029614565880. Epub 2015 Jan 19.
7
P-selectin-deficient mice to study pathophysiology of sickle cell disease.
Blood Adv. 2020 Jan 28;4(2):266-273. doi: 10.1182/bloodadvances.2019000603.
8
P-selectin plays a role in haem-induced acute lung injury in sickle mice.
Br J Haematol. 2019 Jul;186(2):329-333. doi: 10.1111/bjh.15807. Epub 2019 Feb 27.
9
MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
FASEB J. 2016 Mar;30(3):1171-86. doi: 10.1096/fj.15-278481. Epub 2015 Nov 30.
10
Platelet P-selectin expression in patients with sickle cell disease who undergo apheresis.
Ther Apher Dial. 2007 Aug;11(4):255-61. doi: 10.1111/j.1744-9987.2007.00475.x.
引用本文的文献
1
Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation.
Blood Vessel Thromb Hemost. 2024 Jun 18;1(3):100015. doi: 10.1016/j.bvth.2024.100015. eCollection 2024 Sep.
2
OcclusionChip: A functional microcapillary occlusion assay complementary to ektacytometry for detection of small-fraction red blood cells with abnormal deformability.
Front Physiol. 2022 Aug 25;13:954106. doi: 10.3389/fphys.2022.954106. eCollection 2022.
本文引用的文献
1
P-selectin deficiency promotes liver senescence in sickle cell disease mice.
Blood. 2021 May 13;137(19):2676-2680. doi: 10.1182/blood.2020009779.
2
Co-option of Neutrophil Fates by Tissue Environments.
Cell. 2020 Nov 25;183(5):1282-1297.e18. doi: 10.1016/j.cell.2020.10.003. Epub 2020 Oct 23.
3
Liver Macrophages: Old Dogmas and New Insights.
Hepatol Commun. 2019 Apr 22;3(6):730-743. doi: 10.1002/hep4.1356. eCollection 2019 Jun.
4
Pathophysiology of Sickle Cell Disease.
Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17.
5
Sickle cell disease.
Nat Rev Dis Primers. 2018 Mar 15;4:18010. doi: 10.1038/nrdp.2018.10.
6
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.
7
Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage.
Exp Hematol. 2016 Oct;44(10):940-6. doi: 10.1016/j.exphem.2016.06.252. Epub 2016 Jul 5.
8
Neutrophil ageing is regulated by the microbiome.
Nature. 2015 Sep 24;525(7570):528-32. doi: 10.1038/nature15367. Epub 2015 Sep 16.
9
The vessel wall and its interactions.
Blood. 2008 Jun 1;111(11):5271-81. doi: 10.1182/blood-2008-01-078204.
10
Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice.
Cell. 1993 Aug 13;74(3):541-54. doi: 10.1016/0092-8674(93)80055-j.
Zotero 插件